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We report the clinical course of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) in two Japanese teenagers.
Patient 1: :A 17-year-old girl complained of a fever, sore throat, and back pain for 2 days. A nasopharyngeal swab
polymerase chain reaction (PCR) test for SARS-CoV-2 revealed positivity on the 17th day after the onset of symp-
toms. There was no remarkable change in complete blood count (CBC) and biochemical data. The virus tested
negative on day 23. Patient 2: A 14-year-old girl, the sister of patient 1, complained of cough alone, and a nasopha-
ryngeal swab PCR test revealed positivity for SARS-CoV-2 on the first day of the onset of symptoms. Her symp-
toms improved 3 days later. There were no remarkable changes in CBC and biochemical data on a blood test or
findings of chest X-ray screening. The virus tested negative on day 10.
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Figure 1 Timelines of symptoms, PCR testing, and hospitalization duration of both pa-
tients.
SARS-CoV-2 tested negative on day 23 for patient 1 and day 10 for patient 2.
PCR, polymerase chain reaction; PT, patient.
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Both patients exhibited mild symptoms for only a few days. Neither of the patients developed severe pneumonia
or acute respiratory distress syndrome. However, it took 23 days for patient 1 and 10 days for patient 2 from the
onset of the first symptoms for the virus to test negative on nasopharyngeal swab PCR testing. These cases indi-
cate that patients with mild symptoms may spread the SARS-CoV-2 for the same duration as that of symptomatic
patients. Hence, infection control among asymptomatic patients is very important to avoid human-to-human
transmission in families or communities.
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RNA Mini Kit（QIAGEN K.K.，東京）を用いて RNA
を 抽 出 し，QuantStudio 5リ ア ル タ イ ム PCR
（Thermo Fisher Scientific K.K.，東京）を使用したリ

















第 19病日に当科に入院した．症状発症 5日前に 300
人規模の閉鎖空間でのイベントに参加していた．
現症：体温 37.0℃，血圧 102/50 mmHg，脈拍 78/
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Figure　2　Chest X-ray image of patient 1.
No pneumonia or pulmonary vascular congestion was ob-
served.
Table　1　Laboratory findings of both patients at 
hospitalization.
Patient 1 Patient 2
From disease onset (days) 21 3
WBC (/μL) 7,700 8,150
Neut (%) 63.3 54.2
Lymp (%) 30.3 34.4
Mono (%) 4.9 5.2
Eos (%) 1.0 6.0
Baso (%) 0.5 0.2
RBC (×106/μL) 4.82 4.87
Hb (g/dL) 14.0 14.2
Ht (%) 40.4 41.7
Plt (×103/μL) 279 184
TP (g/dL) 7.8 7.3
Alb (g/dL) 4.7 4.4
AST (U/L) 17 18
ALT (U/L) 26 17
LDH (U/L) 168 197
BUN (mg/dL) 12 18
Cr (mg/dL) 0.61 0.73
UA (mg/dL) 4.0 3.8
Na (mEq/L) 139 139
K (mEq/L) 4.0 4.5
Cl (mEq/L) 103 103
CRP (mg/dL) 0.02 0.04
D-dimer (μg/mL) 1.1 0.5
Ferritin (ng/mL) 66.8 32.2

















入院 3日目（第 21病日）に 1度目の PCR検査で陰
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